Annals of Surgical Oncology

, Volume 20, Issue 10, pp 3254–3258

Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort

  • Rachel Greenup
  • Adam Buchanan
  • Wendy Lorizio
  • Keelia Rhoads
  • Salina Chan
  • Tracey Leedom
  • Robin King
  • Jane McLennan
  • Beth Crawford
  • P. Kelly Marcom
  • E. Shelley Hwang
Breast Oncology

Abstract

Background

Revised NCCN guidelines recommend that women ≤60 years with triple-negative breast cancer (TNBC) be referred for consideration of genetic counseling. Small, homogeneous samples have limited evaluation of BRCA mutation prevalence among different ethnicities affected by TNBC subtype. We sought to determine whether the prevalence of BRCA mutations within a TNBC cohort differs by demographic factors.

Methods

We performed a retrospective review of patients with TNBC referred for genetic counseling at two academic Hereditary Cancer Clinics between 2000 and 2012. Demographic data were collected, including age at diagnosis and race/ethnicity. Race was categorized as African American (AA), Ashkenazi Jewish (AJ), Asian, Caucasian, Hispanic, or other. Primary outcome was BRCA mutation status, analyzed by race/ethnicity and age at diagnosis.

Results

A total of 469 patients with TNBC who underwent testing for BRCA genetic mutations were identified, of which 450 patients had evaluable BRCA testing results; 139 (30.8 %) had confirmed BRCA1 (n = 106) or BRCA2 (n = 32) mutations. BRCA mutation prevalence differed by ethnicity and race: AA (20.4 %), AJ (50 %), Asian (28.5 %), Caucasian (33.3 %), and Hispanic (20 %). The prevalence of genetic mutations also differed by age at diagnosis: <40 years (43.8 %), 40–49 years (27.4 %), 50–59 years (25.3 %), 60–69 years (12.5 %), and >70 years (16.6 %).

Conclusions

The prevalence of genetic mutations among women with TNBC referred for genetic counseling is high and differs significantly by ethnicity/race and age. This data helps to refine mutation risk estimates among women with TNBC, allowing for more personalized genetic counseling potentially aiding in improved patient decision-making.

References

  1. 1.
    Daly MB, Axilbund JE, Buys S, et al. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Cancer Netw. 2010;8:562–94.Google Scholar
  2. 2.
    Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009;9:86.PubMedCrossRefGoogle Scholar
  3. 3.
    Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple-negative breast cancer. Clin Cancer Res. 2011;17(5):1082–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118:2787–95.PubMedCrossRefGoogle Scholar
  5. 5.
    Robertson L, Hanson H, Seal S, et al. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years. Br J Cancer. 2012;106:1234–8.PubMedCrossRefGoogle Scholar
  6. 6.
    National Comprehensive Cancer Network, NCCN Guidelines Version 2.2013. Hereditary Breast and/or Ovarian Cancer Syndrome. NCCN.org. Google Scholar
  7. 7.
    Comen E, Davids M, Kirchoff T, et al. Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi women. Breast Cancer Res Treat. 2011;129:185–90.PubMedCrossRefGoogle Scholar
  8. 8.
    Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst. 1999;91:1241–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Armstrong K, Calzone K, Stopfer J, et al. Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomark Prev. 2000;9:1251.Google Scholar
  10. 10.
    Hall MJ, Reid JE, Burbige LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer. 2009;115:2222–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Berry DA, Iversen ES, Gudbjartsson DF, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20:2701–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Tai YC, Chen S, Parmigiani C, et al. Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction. Breast Cancer Res. 2008;10(2):401.PubMedCrossRefGoogle Scholar
  13. 13.
    Kwon JS, Gutierrez-Barrera AM, Young D, et al. Expanding the criteria for BRCA mutation testing breast cancer survivors. J Clin Oncol. 2010;28:4214–20.PubMedCrossRefGoogle Scholar
  14. 14.
    Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28:893–901.PubMedCrossRefGoogle Scholar
  15. 15.
    American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397–406.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Rachel Greenup
    • 1
    • 3
  • Adam Buchanan
    • 3
  • Wendy Lorizio
    • 1
  • Keelia Rhoads
    • 3
  • Salina Chan
    • 4
  • Tracey Leedom
    • 3
  • Robin King
    • 3
  • Jane McLennan
    • 4
  • Beth Crawford
    • 4
  • P. Kelly Marcom
    • 2
    • 3
  • E. Shelley Hwang
    • 1
    • 3
  1. 1.Department of SurgeryDuke UniversityDurhamUSA
  2. 2.Department of MedicineDuke UniversityDurhamUSA
  3. 3.Duke Cancer InstituteDurhamUSA
  4. 4.University of California San Francisco Comprehensive Cancer CenterSan FranciscoUSA

Personalised recommendations